Next 10 |
home / stock / agen / agen articles
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial result...
U.S. stocks were mixed, with the Dow Jones index gaining around 20 points on Tuesday. Shares of Saia Inc (NASDAQ:SAIA) rose sharply during today...
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, whic...
Friday, Agenus Inc (NASDAQ:AGEN) released updated results from its Phase 1 clinical trial of botensilimab and balstilimab (BOT/BAL) combi...
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 0.1% on Monday. The Dow traded up 0.04% to 38,919.32 ...
Shares of Agenus Inc. (NASDAQ: AGEN) fell sharply during Monday’s session. Agenus disclosed a 1-for-20 reverse stock split of common stock. A...
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 50 points on Monday. The Dow traded up 0.21% to 38,983.94 ...
With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: Accenture plc (...
BOSTON and LEXINGTON, Mass., Feb. 15, 2024 /PRNewswire/ -- The Defense Threat Reduction Agency's (DTRA) Joint Science and Technology Office (J...
News, Short Squeeze, Breakout and More Instantly...
Extended BOT/BAL Therapy Yields Pronounced Improvements in Tumor Reductions Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilim...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that the Cancer Therapy Evaluation Program (CTEP) is accepting Letters of Intent (LOIs) to conduct clinical studies using botensilimab (BOT), a huma...
2024-06-27 01:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...